AKR1B10 and metabolic dysfunction-associated steatotic liver disease: Using a high-throughput RNA-seq approach in a cohort of 206 NAFLD biopsies to understand the pathogenesis disease progression, we recently showed that changes in transcription of the epithelial markers AKR1B10 and GDF15 can also lead to altered circulating concentrations of these proteins, serving as putative biomarkers for fibrosing-steatohepatitis14.